Items where Author is "Thuerlimann, B."
Jump to: Article Number of items: 4. ArticleJoerger, M. and Schaer-Thuer, C. and Koeberle, D. and Matter-Walstra, K. and Gibbons-Marsico, J. and Diem, S. and Thuerlimann, B. and Cerny, T.. (2014) Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. European Journal of Clinical Pharmacology, 70 (6). p. 719. Koeberle, D. and Ruhstaller, T. and Jost, L. and Pagani, O. and Zaman, K. and von Moos, R. and Oehlschlegel, C. and Crowe, S. and Pilop, C. and Thuerlimann, B. and Swiss Grp Clinical Canc Res Sakk, . (2011) Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer : a proof-of-concept trial (SAKK 23/03). Endocrine related cancer, Vol. 18, H. 2. pp. 257-264. Hawle, H. and Hess, D. and Mueller, A. and Thuerlimann, B.. (2010) Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Reports in Oncology, 3 (2). pp. 131-136. Greuter, S. and Schmid, F. and Ruhstaller, T. and Thuerlimann, B.. (2008) Bevacizumab-associated osteonecrosis of the jaw. Annals of oncology, Vol. 19, H. 12. pp. 2091-2092. |
